Johnson & Johnson has announced initial Phase 1 results for JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody, in patients with relapsed or refractory multiple myeloma. The trial demonstrated encouraging clinical activity, with an overall response rate of 86.1 percent among the 36 patients who received the recommended phase 2 dose. In patients who were naive to BCMA and GPRC5D directed therapies, the overall response rate was 100 percent. The trispecific antibody targets B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells. These findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting and will be featured at the 2025 European Hematology Association Congress. Further studies on JNJ-5322 are planned to explore its potential as a treatment option for multiple myeloma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.